You are here

  • Home
  • Archive
  • Volume 16, Issue 2
  • Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD study

Article info

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD study

Authors

  1. Correspondence to David R Matthews
    Oxford Centre for Diabetes and Endocrinology, Churchill Hospital, Oxford, OX3 7LJ, UK; david.matthews{at}ocdemox.ac.uk
View Full Text

Citation

Matthews DR
Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD study
BMJ Evidence-Based Medicine 2011;16:45-46.

Publication history

  • First published March 21, 2011.
Online issue publication 
October 25, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions